Treating the Host Response to Ebola Virus Disease with Generic Statins and Angiotensin Receptor Blockers

Treatments targeting the Ebola virus may eventually be shown to work, but they will not have an impact on overall Ebola mortality in West Africa. Endothelial dysfunction is responsible for the fluid and electrolyte imbalances seen in Ebola patients. Because inexpensive generic statins and angiotensi...

Full description

Saved in:
Bibliographic Details
Published in:mBio 2015-06, Vol.6 (3), p.e00716-e00716
Main Authors: Fedson, David S, Jacobson, Jeffrey R, Rordam, Ole Martin, Opal, Steven M
Format: Article
Language:English
Subjects:
Africa, Western
Angiotensin Receptor Antagonists - therapeutic use
Endothelial Cells - drug effects
Endothelial Cells - physiology
Hemorrhagic Fever, Ebola - drug therapy
Humans
Hydroxymethylglutaryl CoA Reductases - therapeutic use
Opinion/Hypothesis
Sierra Leone
Survival Analysis
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Treatments targeting the Ebola virus may eventually be shown to work, but they will not have an impact on overall Ebola mortality in West Africa. Endothelial dysfunction is responsible for the fluid and electrolyte imbalances seen in Ebola patients. Because inexpensive generic statins and angiotensin receptor blockers restore endothelial barrier integrity, they can be used to treat the host response in these patients. In Sierra Leone, approximately 100 Ebola patients were treated with this combination, and reports indicate that survival was greatly improved.
ISSN:2161-2129
2150-7511
DOI:10.1128/mBio.00716-15